To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 22, 2019___

Today's Rundown

Featured Story

Biogen bullish on prospects of Alzheimer's drug aducanumab

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite it failing an interim analysis in phase 3.

Top Stories

Horizon sets up shop in Bay Area at it ramps up R&D, manufacturing

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco. It plans to explore the biotech hub for new partnerships and add jobs spanning the areas of bioanalysis, clinical research, pharmacology, manufacturing and business development.

Azeria raises £32M to take breast cancer drug into humans

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic. The money will fund work on small molecule inhibitors of FOXA1, a pioneer factor involved in tumor development.

Mount Sinai researchers uncover new genetic drivers of Parkinson's disease

Researchers at the Mount Sinai Icahn School of Medicine used a statistical method called multiscale gene network analysis to identify the gene STMN2 as a key regulator of Parkinson’s disease. They believe the discovery could aid the development of targeted therapies for Parkinson's.

EuroBiotech Report—Bayer's phase 3 success, U.K. trial investment, EU fund, MorphoSys and Tissium

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

FiercePharmaAsia—Novartis' Shanghai R&D revamp; BeiGene’s Imbruvica rival; Shionogi’s antibiotic

Novartis is shutting down its Shanghai R&D site's discovery function in favor of drug development. BeiGene nabbed a landmark FDA nod for Brukinsa, a challenger to J&J and AbbVie's Imbruvica. Shionogi's antibiotic Fetroja won FDA approval with a mortality warning. And more.

Chutes & Ladders—Yumanity snags ex-Shire exec Robertson as CMO

Yumanity nabs ex-Shire exec Robertson as CMO; DiMartino new R&D chief at Kronos; Longtime Arrowhead exec Given steps down.

Enrollment Showcase

A Credential for the Future of Health Care

Join the future of health care with the flexibility and convenience of an online program.

Resources

[Whitepaper] Modernizing clinical trials with Amazon Web Services (AWS)

From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks

[Whitepaper] Why Companies Leverage the Cloud to Smooth the Path to FDA Approval

See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate.

[Whitepaper] Medical Affairs 2025 Excellence in the Era of Precision Medicine

Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade.

[Whitepaper] The State of Real-World Evidence in Biopharma

This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow.

[Whitepaper] IBM Clinical Development: Key solutions for more efficient clinical research

IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology.

[Whitepaper] How Big is the US Market for Medical Devices and Technologies?

Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting.

[Whitepaper] The importance of early key opinion leader outreach in the biologics and biosimilars marketplace

Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more.

[Whitepaper] 5 Best Practices for Marketing Medical Devices

Discover solutions to the most common challenges faced by medical device companies.

[Whitepaper] The Impact of Step-Therapy Policies on Patients

Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system.

[Whitepaper] Q2 2019 Biopharma licensing report

18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights.

[Whitepaper] Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start

Is your API development on track?

[Infographic] Implement the Patient Voice to Build an Effective Engagement App

Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app.

[eBook] Customer Experience: Shaping Digital Healthcare

Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve

[Whitepaper] How to succeed by failing faster

This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy.

[Whitepaper] Innovative Funding Models for Treatment of Cancer and Other High-Cost Chronic Noncommunicable Diseases

A global landscape study of funding trends and innovations.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events